Extranodal Natural Killers/T Cell´s Lymphoma: A case report.
Keywords:
NK/T Cell Lymphoma, ENKTL, Natural Killers, Non-Hodgkin Lymphoma, Cancer.Abstract
Introduction: Extranodal Natural Killers/T Cell´s lymphomas are uncommon diseases with a higher incidence in the regions of East Asia and Central and South America and are associated with the Epstein-Barr virus. These neoplasms have a tendency to affect the facial midline, mainly the nasal and paranasal regions. These diseases develop an angiocentric growth pattern with necrosis. These lymphomas have aggressive behavior and high mortality.
Objective: The objective of this work is to present a rare case of NK/T-cell lymphoma, which should be taken into account since its late diagnosis influences the high lethality and poor survival.
Case Presentation: Here we present a case of an Extranodal Natural Killers/T Cell´s lymphoma in a 21 years old male with a febrile picture of long-standing evolution (3 months), nasal obstruction, weight loss, and swelling of the zygomatic arch, accompanied by tumor infiltration, destruction of the palate, and purulent discharge through the left eye. The symptoms and signs occurred over a period of approximately 4 months, with a progressive deterioration of the patient.
Conclusion: Even though Extranodal Natural Killers/T Cell´s lymphoma is an uncommon disease, it has an aggressive clinical course with poor prognosis and survival. Therefore, it should be considered in the differential diagnosis of nasal or paranasal swelling.
Downloads
References
1. Kommalapati A, Tella SH, Ganti AK, Armitage JO. Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States. Clin Lymphoma Myeloma Leuk. 2018 Jul 1;18(7):475–9.
2. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022 36:7 [Internet]. 2022 Jun 22 [cited 2022 Aug 28];36(7):1720–48. Available from: https://www.nature.com/articles/s41375-022-01620-2
3. Asano N, Kato S, Nakamura S. Epstein–Barr virus-associated natural killer/T-cell lymphomas. Best Pract Res Clin Haematol. 2013 Mar;26(1):15–21.
4. Bajor-Dattilo EB, Pittaluga S, Jaffe ES. Pathobiology of T-cell and NK-cell lymphomas. Best Pract Res Clin Haematol. 2013 Mar;26(1):75–87.
5. Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, et al. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol. 2020 Apr 1;7(4):e284–94.
6. Peng RJ, Han BW, Cai QQ, Zuo XY, Xia T, Chen JR, et al. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. Leukemia [Internet]. 2019;33(6):1451–62. Available from: https://doi.org/10.1038/s41375-018-0324-5
7. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar 1;65(2):87–108.
8. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiology Biomarkers & Prevention. 2016 Jan 12;25(1):16 LP – 27.
9. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Sep 1;n/a-n/a.
10. William BM, Armitage JO. International analysis of the frequency and outcomes of NK/T-cell lymphomas. Best Pract Res Clin Haematol. 2013 Mar;26(1):23–32.
11. Jhuang JY, Chang ST, Weng SF, Pan ST, Chu PY, Hsieh PP, et al. Extranodal natural killer/T-cell lymphoma, nasal type in Taiwan: a relatively higher frequency of T-cell lineage and poor survival for extranasal tumors. Hum Pathol. 2015 Feb;46(2):313–21.
12. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May 1 [cited 2022 Jun 6];71(3):209–49. Available from: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21660
13. Saleem A, Natkunam Y. Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis. International Journal of Molecular Sciences 2020, Vol 21, Page 1501 [Internet]. 2020 Feb 22 [cited 2022 Aug 28];21(4):1501. Available from: https://www.mdpi.com/1422-0067/21/4/1501/htm
14. Montes-Mojarro IA, Fend F, Quintanilla-Martinez L. EBV and the Pathogenesis of NK/T Cell Lymphoma. Cancers 2021, Vol 13, Page 1414 [Internet]. 2021 Mar 19 [cited 2022 Aug 28];13(6):1414. Available from: https://www.mdpi.com/2072-6694/13/6/1414/htm
15. de Mel S, Soon GST, Mok Y, Chung TH, Jeyasekharan AD, Chng WJ, et al. The genomics and molecular biology of natural killer/T-cell lymphoma: Opportunities for translation. Int J Mol Sci [Internet]. 2018;19(7). Available from: www.mdpi.com/journal/ijms
16. Lin GW, Xu C, Chen K, Huang HQ, Chen J, Song B, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol. 2020 Feb 1;21(2):306–16.
17. Li Z, Xia Y, Feng LN, Chen JR, Li HM, Cui J, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol. 2016 Sep 1;17(9):1240–7.
18. Dong G, Liu X, Wang L, Yin W, Bouska A, Gong Q, et al. Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma. Leukemia 2022 36:8 [Internet]. 2022 Jun 13 [cited 2022 Aug 28];36(8):2064–75. Available from: https://www.nature.com/articles/s41375-022-01623-z
19. Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood [Internet]. 2018 Sep 13 [cited 2022 Aug 11];132(11):1146–58. Available from: https://ashpublications.org/blood/article/132/11/1146/39381/Oncogenic-activation-of-the-STAT3-pathway-drives
20. Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell. 2020 Mar 16;37(3):403-419.e6.
21. Zhang Y, Li C, Xue W, Zhang M, Li Z. Frequent Mutations in Natural Killer/T Cell Lymphoma. Cellular Physiology and Biochemistry [Internet]. 2018 Sep 1 [cited 2022 Aug 11];49(1):1–16. Available from: https://www.karger.com/Article/FullText/492835
22. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, et al. Extranodal NK/T-cell Lymphoma, Nasal Type: A Report of 73 Cases at MD Anderson Cancer Center. Am J Surg Pathol [Internet]. 2013;37(1). Available from: http://journals.lww.com/ajsp/Fulltext/2013/01000/Extranodal_NK_T_cell_Lymphoma,_Nasal_Type__A.2.aspx
23. Yamaguchi M, Suzuki R, Oguchi M, Asano N, Amaki J, Akiba T, et al. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan. Journal of Clinical Oncology. 2016 Oct 3;
24. Tse E, Kwong YL. NK/T-cell lymphomas. Best Pract Res Clin Haematol. 2019 Sep 1;32(3):253–61.
25. Suzuki R. Pathogenesis and Treatment of Extranodal Natural Killer/T-Cell Lymphoma. Semin Hematol. 2014 Jan;51(1):42–51.
26. Tse E, Au-Yeung R, Kwong YL. Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. https://doi.org/101080/1747408620191660640 [Internet]. 2019 Nov 2 [cited 2022 Aug 28];12(11):927–35. Available from: https://www.tandfonline.com/doi/abs/10.1080/17474086.2019.1660640
27. Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood [Internet]. 2018 Jun 7 [cited 2022 Aug 28];131(23):2528–40. Available from: https://ashpublications.org/blood/article/131/23/2528/36945/Advances-in-the-treatment-of-extranodal-NK-T-cell
28. van Doesum JA, Niezink AGH, Huls GA, Beijert M, Diepstra A, van Meerten T. Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment. Hemasphere [Internet]. 2021 Feb 12 [cited 2022 Aug 28];5(2). Available from: /pmc/articles/PMC7806244/
29. Wang X, Hu J, Dong M, Ding M, Zhu L, Wu J, et al. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients. Clin Transl Sci [Internet]. 2021 Jan 1 [cited 2022 Aug 28];14(1):405–11. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/cts.12893
Download PDF
